Notably, the JUNIPER trial in KRASMUT lung cancer has showed that the CDK4/6i Abemaciclib performed better than the EGFR inhibitor Erlotinib, in term of both objective responses and progression free survival (NCT02152631). Here, CDK4 is linked to lung cancer.